Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 23Prednisone 16N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Vincristine 11Doxorubicin 11Etoposide 9fludarabine phosphate 8Whole-Body Irradiation 8Mycophenolic Acid 7Lenalidomide 7Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6Brentuximab Vedotin 6Azacitidine 6Alemtuzumab 6Cyclosporine 5Bortezomib 5romidepsin 4fludarabine 4Tacrolimus 4Rituximab 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4pembrolizumab 3denileukin diftitox 3Transplantation 3Dexamethasone 3Carmustine 3Busulfan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell, Peripheral × HBI-8000 × Clear all
NCT05833724 2025-03-11

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Great Novel Therapeutics Biotech & Medicals Corporation

Phase 2 Recruiting
33 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02953652 2024-09-19

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

HUYABIO International, LLC.

Phase 2 Completed
55 enrolled 18 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡